Tag Archives: Illumina

November, 2018

2 November
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery

SAN DIEGO & MENLO PARK, Calif.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB) today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ …
Share

15 May
Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis

mina SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to …
Share

16 April
Bristol-Myers Squibb and Illumina Partner for Companion Diagnostics for Oncology Immunotherapies

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina …
Share
10 April
Illumina and Loxo Oncology Partner for Development of Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

SAN DIEGO & STAMFORD, Conn.–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication. The co-development partnership will …
Share

30 June
Illumina Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the …
Share

3 April
Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC

umin SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced it is contributing more than 8,000 associations of somatic genetic alterations—variants linked to tumors—to the Clinical Interpretation of Variants in Cancer (CIViC) resource, an openly accessible database hosted by Washington University in St. Louis that can be used in precision medicine. …
Share

2 December
Illumina Launches iHope Program Aimed at Identifying Undiagnosed Rare Diseases in Children

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced the iHope program, a philanthropic initiative aimed at identifying the genetic causes of undiagnosed rare diseases in children. With initial program partners Foundation for the Children of the Californias, Rare Genomics Institute, and UCSF Benioff Children’s Hospital San Francisco, selected patients in …
Share

11 November
Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing

SAN DIEGO & ROCHESTER, Minn.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an agreement with Mayo Clinic to make advancements in next-generation sequencing technology with the intent to accelerate Mayo’s delivery of genetic and genomic expertise. Together, the organizations plan to integrate existing services and software tools and …
Share

9 May
Collaborative Study of Whole Exome Sequencing Offers New Hope for Children with White Matter Disorders

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN), Children’s National Health System and The University of Queensland (UQ) announced today that a study using whole exome sequencing (WES), a method to look at all the genes in the genome at once, yielded clinical diagnoses for 42 percent of patients with white matter abnormalities …
Share

27 January
Illumina Acquires Conexio Genomics

Building on Illumina’s work to develop next-generation sequencing (NGS) solutions for the HLA typing market, Illumina recently announced its acquisition of Conexio Genomics, a world leader in the development of HLA typing solutions. “The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to …
Share

Page 1 of 212 »